Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
Status:
Withdrawn
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of
the molecular chaperone heat shock protein 90 (HSP90). Hsp90 inhibitors may overcome
ibrutinib resistance in Mantle cell lymphomas and this study will investigate whether the
addition of SNX-5422 to an established dose of ibrutinib will result in the removal of
mutated BTK from blood mononuclear cells and/or prevents or delays disease progression of
subjects with CLL